1. Introduction {#s0005}
===============

Cardiovascular disease remains the most common cause of mortality worldwide, accounting for more than 17 million deaths annually ([@bb0015]). Myocardial infarction (MI) leads to irreversible myocardial sequelae, often causing debilitating symptoms and shortening life span. Recently, biological regenerative innovations have been introduced as promising therapeutic options ([@bb0110], [@bb0045], [@bb0085]).

Cardiac fat contains a population of mesenchymal-like progenitor cells capable of differentiating into cells that closely resemble cardiomyocytes, both morphologically and molecularly. In murine MI models, these cells improved cardiac function parameters and promoted local neoangiogenesis under hypoxia ([@bb0025]). The adipose tissue surrounding the heart and pericardium may serve as an autologous biological matrix for salvaging injured myocardium.

The Adipose Graft Transposition Procedure (AGTP) uses patient\'s existing cardiac fat directly, placing it over the myocardial infarcted zones, rather than explanting a cardiac adipose biopsy to retrieve the cells ([@bb0040], [@bb0050]). In the acute MI porcine model, functional analyses showed an improvement in LVEF in the AGTP-treated arm five-fold higher than untreated animals ([@bb0040]). In the chronic MI porcine model, morphometry revealed a 34% reduction in left ventricular infarct area of AGTP-treated relative to control animals ([@bb0050]). These preclinical studies in a large mammal model suggest that AGTP may be an effective post MI treatment for patients. Accordingly, a prospective randomized trial was set up to assess safety and efficacy of AGTP in patients with a myocardial scar.

2. Patients and Methods {#s0010}
=======================

2.1. Patients {#s0015}
-------------

The study included 10 candidates for myocardial revascularization with an established chronic transmural myocardial scar, from January 2012 to November 2013. Inclusion criteria included patients ≥ 18 years of age, with an established transmural MI (minimum three months old) anatomically non amenable for surgical revascularization, and candidates for coronary artery bypass graft (CABG) surgery of other arteries non responsible for the transmural scar. A non-revascularizable area was defined as a chronic transmural necrosis detected by means of late gadolinium enhancement \> 70% of myocardial thickness on MRI.

Exclusion criteria were: severe valvular disease apt for surgery, candidates to surgical ventricular remodeling, contraindication for MRI, extra-cardiac disease with life expectancy \< 1 year, severe renal or hepatic insufficiency, previous cardiac surgery, very high surgical risk by EuroSCORE (\> 8), and pregnant or breastfeeding women.

2.2. Study Design and AGTP Intervention {#s0020}
---------------------------------------

This study was a prospective, single-center, randomized controlled phase I---II clinical trial (ClinicalTrials.gov number [NCT01473433](ctgov:NCT01473433){#ir0010}, AdiFLAP Trial). It was designed and implemented in accordance with the Declaration of Helsinki; informed consent was obtained from all participating patients.

Enrolled patients were randomly allocated in 2 arms ([Fig. 1](#f0005){ref-type="fig"}):--Control arm (n = 5): Patients in whom the revascularizable area was treated with CABG and the non-revascularizable area was left untouched.--AGTP-treated arm (n = 5): Patients in whom the revascularizable area was treated with CABG and the non-revascularizable area was covered by an autologous pericardial adipose graft. [Fig. 2](#f0010){ref-type="fig"} summarizes the steps of the AGTP intervention. First, to obtain the graft, the pericardial adipose tissue was detached with its vascularization intact (depending on scar location, the adipose tissue was detached from the left or the right side of the pericardium as needed); next, after pericardiotomy, the vascular adipose graft was gently positioned to ensure full coverage of the necrotic zone; finally, to secure the flap, the edges were adhered to bordering healthy myocardium with commercially available cyanoacrylic-based surgical glue (Glubran®2, USA) ([@bb0040], [@bb0050], [@bb0020], [@bb0095]).

The clinical cardiologist handling postsurgical care and the MRI specialist were both blind to the participants\' treatment. Study visits consisted of a baseline visit (obtained informed consent and performed clinical assessment, including MRI), surgical intervention, and follow-up visits at one week (clinical assessment), three and 12 months (clinical assessment including MRI) after procedure.

Safety of the procedure was evaluated by the presence of major clinical events including hospital admissions and death, and by the results of a 24-hour Holter monitor test done at each study visit to assess arrhythmias. Efficacy was assessed by left ventricular ejection fraction (LVEF), cardiac output (CO), stroke volume (SV), end-diastolic wall mass (EDWM), left ventricular end-diastolic (LVEDV) and end-systolic volume (LVESV) by means of cardiac-MRI. NTproBNP, troponin I (TnI), NYHA functional class and Framingham derived clinical score were also assessed.

2.3. Cardiac MRI Data Acquisition and Analysis {#s0025}
----------------------------------------------

All imaging were performed in a state-of-the-art 1.5 T clinical imaging system (Avanto; Siemens Medical Imaging, Erlangen, Germany) with the patient in the supine position and a 16-element phased-array coil placed over the chest. Images were acquired during breath-holds with ECG gating. We used a segmented k-space steady-state free-precession sequence \[RT 44.70 ms; echo time 1.26 ms; flip angle 78; matrix 272; spatial resolution (1.3--1.5)×(1.3--1.5) × 8 mm depending on the field of view\] for cine imaging in parallel short-axis (contiguous slices of 8-mm thickness covering from base to apex) and 3 long-axis views of the left ventricle. Delayed enhancement images were acquired with a segmented gradient-echo inversion-recovery sequence \[RT (600--800) ms depending on the cardiac heart rate; echo time 3.24 ms; flip angle 25; matrix 256; spatial resolution 1.3 × 1.3 × 8 mm\] at matching cine-image slice locations 10 to 20 min after intravenous gadolinium-DTPA administration (0.20 mmol/kg; Gadovist, Bayer Schering Pharma AG, Berlin, Germany) ([@bb0105]). We optimized the inversion time to null the normal myocardium and adjusted views per segment and trigger delay according to the patient\'s heart rate. Native and post contrast cardiac T1 mapping was calculated using a modified Look--Locker inversion recovery sequence (MOLLI) in a short axis view at the infarct level ([@bb0075], [@bb0130], [@bb0065], [@bb0070]).

All images were reviewed and analyzed off-line with a specialized post-processing software (QMass-MR, v.7·0; Medis Medical Imaging Systems, Leiden, the Netherlands) by an independent core lab, which collected and interpreted all imaging data blinded to the clinical data and outcome (J.A.S., A.R.: ICICORELAB, Valladolid, Spain; A.T.). LV endocardial border (papillary muscles were excluded) were manually traced on all short-axis cine images at the end-diastolic and end-systolic frames to determine the LV end-diastolic and LV end-systolic volumes, respectively. LV mass was calculated by subtracting the endocardial volume from the epicardial volume at end diastole and then multiplying by the tissue density (1.05 g/mL) ([@bb0060]).

The endocardial and epicardial contours on delayed enhancement images were also outlined manually. ROIs were then manually traced in the hyperenhanced area at place of maximum signal intensity and in the normal-appearing remote myocardium. As previously described, the areas of hyperenhancing myocardium were then automatically segmented by using a full-width at half-maximum (FWHM) algorithm ([@bb0035], [@bb0010]). Two corrections were required for all automated ROIs. First, microvascular obstruction (defined as hypointensity within a hyperintense region in patients with infarctions) was adjusted to be included as late gadolinium enhancement (LGE) if present. Second, any obvious blood pool or pericardial partial voluming and artefacts were further removed from the ROI.

Scar volume for each slice was calculated as: area scar × slice thickness. The scar mass was expressed as total scar volume × 1.05 g. The scar percentage of myocardium was also expressed as a percentage of the total myocardial volume: volume scar / volume myocardium × 100.

T1 mapping derived extracellular volume (ECV) of the necrotic area was estimated using the native and post-contrast myocardial and blood pool T1 maps, accounting for the patient hematocrit at the time of exploration. The T1 map ROI was manually traced covering the entire necrotic area avoiding any blood pool or pericardial partial voluming or artefact. Moreover, areas of microvascular obstruction or fatty infiltration were excluded from the T1 mapping calculation in order to avoid any bias ([@bb0055]).

2.4. Statistical Analysis {#s0030}
-------------------------

Descriptive analyses were performed at the first step. Categorical variables were described by frequencies and percentages. Continuous variables were described by means and standard deviations or medians and interquartile ranges in cases of skewed distribution. Differences between groups were compared using Student\'s t-test or one-way ANOVA for multiple comparisons, with Tukey\'s test for *post hoc* analyses. The comparison of continuous variables between groups was performed using analysis of variance for unpaired data once normality was demonstrated (Kolmogorov--Smirnov test); otherwise, a nonparametric test (Mann--Whitney or Kruskal--Wallis test) was used. MRI data were analyzed as repeated measures using ANOVA with Greenhouse--Geisser correction. A 2-sided p \< 0.05 was considered significant. Statistical analyses were performed using SPSS statistical package 19.0.1 version (SPSS Inc, Chicago, IL, USA).

2.5. Role of the Funding Source {#s0035}
-------------------------------

The funding sources had no such involvement.

3. Results {#s0040}
==========

Ten patients were included, randomly allocated to control (n = 5) or AGTP-treated (n = 5). One patient in the control group (Patient \#2) was excluded after randomization because of MRI claustrophobia, resulting in a total sample size of n = 9. All patients were men and there were no significant differences between groups in clinical variables, nor in variables related to disease severity or surgical risk ([Table 1](#t0005){ref-type="table"}).

The same surgeon performed all interventions (M.C.). Patency of all grafts was confirmed and no adverse events were detected during surgery. [Table 2](#t0010){ref-type="table"} summarizes the surgical characteristics of study patients and [Video 1](#ec0010){ref-type="supplementary-material"} shows an inferior AGTP.

No differences in procedure safety were observed between groups ([Table 3](#t0015){ref-type="table"}). Unrelated to the procedure, one patient died in the AGTP-treated arm after seven months due to colonic adenocarcinoma. There were no differences in hospital admissions during follow-up identified between groups. One hospital admission was registered in each group: in the control arm due to symptomatic hypotension and in the AGTP-treated arm for colonic resection, respectively. 24-hour Holter monitoring during 1-year follow-up showed non-significant differences in arrhythmia prevalence, although the number of supraventricular ectopi in the AGTP-treated arm was reduced ([Table 3](#t0015){ref-type="table"}).

Relative changes in percentage of necrotic tissue from baseline to three months in AGTP-treated and control patients assessed by MRI are shown in [Fig. 3](#f0015){ref-type="fig"}. [Table 4](#t0020){ref-type="table"} shows MRI cardiac function data. Overall, we did not observe significant differences between groups. However, Greenhouse--Geisser analyses, which include inter- and intra-individual changes over time, did reveal a trend for smaller LVESV (p = 0.09) and necrosis ratio (p = 0.06) in the AGTP-treated arm at three months. Infarct site-derived T1 mapping extracellular volume (ECV) estimation revealed no significant reduction in the extracellular space from baseline to 3-month follow-up in AGTP-treated versus control patients (− 4.5% vs. − 1.1%, respectively; p = 0.53). No differences in NTproBNP, TnI, NYHA functional class and Framingham-derived clinical score were found between groups.

One patient in the AGTP-treated arm experienced a remarkable improvement after inferior AGTP ([Fig. 4](#f0020){ref-type="fig"}). At the beginning of the study, he had the largest necrotic area (LV necrotic mass: 33.2%) and the most dilated ventricular chambers (LVEDV: 315.1 mL; LVESV: 218.5 mL) of all participants; 3 months after AGTP treatment LV necrotic mass was reduced by 4.4%, LVEDV by 31.9 mL, and LVESV by 23.8 mL. After one-year follow-up, these numbers had decreased further to 10.8%, 55.2 mL, and 37.8 mL, for LV necrotic mass, LVEDV, and LVESV respectively. Remarkably, Q waves vanished from leads I, II and III in the follow-up ECGs ([Fig. 4](#f0020){ref-type="fig"}).

4. Discussion {#s0045}
=============

The results of this pilot study in a prospective cohort indicate that AGTP is a safe procedure that may be efficacious in selected patients. Given its autologous nature and ease of implementation, the translation of the AGTP technique to clinical practice should not be hampered by technical difficulties, economic restrictions, nor ethical or social considerations.

The mechanism of the positive effects of this biological innovation is uncertain, but one possibility is the establishment of vascular connections between the adipose graft and the underlying myocardium as previously demonstrated in the swine MI model ([@bb0030]). There are few accepted techniques of vascularizing a damaged heart. In brief, direct methods such as the simple insertion of an internal mammary artery into the myocardium through a hole ([@bb0125]) or transmyocardial perforation created with lasers mimicking the sinusoids observed in reptilian hearts ([@bb0115]) have not demonstrated a clear-cut clinical benefit. In contrast, indirect revascularization of damaged organs with vascular grafts has been successfully achieved ([@bb0090], [@bb0080]). Previous reports indicate that following AGTP new microvessels developed, bridging the interface between the adipose vascular graft and adjacent myocardium ([@bb0040], [@bb0050]) thus enabling an exchange of nutrients and progenitors between the biological adipose graft and the underlying myocardial scar.

It is unclear whether the adipose-derived progenitor cells exert a role in the beneficial effect of the AGTP. Recent data suggested that cardiac adipose-derived progenitors have an inherent cardiac-like phenotype and may support heart homeostasis, perhaps as a cell reservoir for renewing myocardial tissue. Indeed, in vivo studies in murine models have clearly shown that cardiac adipose-derived progenitors displayed a beneficial effect in the context of MI. Cell transplantation resulted in improved cardiac function parameters and was associated with a significant increase in infarct-related wall thickness ([@bb0025]). In pre-clinical studies in the porcine model, cell trafficking from the adipose graft to the infarcted myocardium was also observed ([@bb0040]). Finally, adipokines liberated by the graft may exert a positive local effect and should be considered as an alternative mechanism. Many studies have described the myocardium and perivascular adipose tissue as well-known sources of hormones, which might exert important autocrine, paracrine, and endocrine effects ([@bb0005]). Indeed, evidence suggests that adipose-derived hormones can offer cardio-protective effects, including attenuation of cardiomyocyte apoptosis, reduction of infarct size, and modulation of collagen I/III ratios ([@bb0120]).

Identification of AGTP responders is an unresolved challenge, but may ultimately be the key to explaining the case of the AGTP-treated participant in whom the Q waves vanished. This patient, who demonstrated the most severe indicators at the start of the study, experienced the greatest improvement after AGTP treatment. Further research is required to identify the clinical, biochemical and/or MRI characteristics of AGTP optimal candidates.

AGTP-treated patients showed a trend towards smaller ventricular volumes than the control group. These results should be interpreted with caution; nevertheless it is plausible that AGTP exerted some beneficial effect by the adipose matrix wrapping the infarcted area. However, the associated CABG procedure practiced in these patients should not be discarded.

This study has several limitations. It was a pilot study with a small number of enrolled subjects, limiting our ability to generalize findings to the overall population. We were not able to perform an autopsy of the deceased patient to confirm proper apposition of the graft nor for additional studies at the ultrastructural level. However, the derived T1 mapping ECV estimation may reflect an improvement in scar composition. Furthermore, future MRI software refinements may allow a more precise definition of the adipose graft surrounding the heart.

At present, cell therapy has been the most tested biological approach for cardiac regeneration/recovery in humans. Cell therapy is safe, but with controversial benefits measured in surrogate endpoints such as LVEF. The recent multicenter, prospective, randomized open-label TECAM trial evaluated three different bone marrow-derived stem cell approaches in MI (intracoronary bone-marrow mononuclear cell --- BMMC --- injection; mobilization with G-CSF; and both BMMC injection plus G-CSF), none of which resulted in improvement of LVEF or volumes compared with standard MI care ([@bb0100]).

This is the first-in-man study on myocardial adipose grafting and we should be restrained in interpreting the results, but findings suggest an improvement in necrosis area in AGTP-treated patients during early follow-up. Future studies are needed to determine whether this innovation translates to superior cardiac function with longer follow-up. This study provides evidence that use of an autologous vascular adipose graft may be a safe alternative in patients with a chronic myocardial scar. A Phase II---III multicenter, prospective, randomized clinical trial is now being set-up to confirm efficacy of the AGTP intervention.

The following are the supplementary data related to this article.Supplementary Table 1Mean MRI values at baseline, three months and one year follow-up for each patient.Supplementary Table 1Adipose Graft Transposition Procedure video take.Video 1
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![Study design. n: number of patients, CABG: coronary artery bypass graft, AGTP: Adipose Graft Transposition Procedure, MRI: magnetic resonance imaging.](gr1){#f0005}

![Schematic illustration of the Adipose Graft Transposition Procedure (AGTP). Pericardial adipose tissue is dissected to create the graft (A). After partial pericardiectomy, MI is located (B) and the pericardial adipose graft is transposed onto the infarct area and glued on healthy edges (C), covering the ischemic myocardium (D). The figure was designed and hand-drawn by CG-M.](gr2){#f0010}

![MRI analysis: Representative T1 short-axis delayed enhancement images rev\`eal healthy (black) and infarcted myocardium (white) for AGTP-treated and control patients at baseline and 12 months. Arrowheads point out the attached adipose graft position in the treated patients. Histograms represent changes in percentage of necrotic tissue from baseline to three months in treated and control patients.](gr3){#f0015}

![Selected patient case: short-axis delayed enhanced images show the healthy (black) and infarcted myocardium (white) before and after AGTP; 4-chamber view shows patient\'s volumes before and after AGTP. Arrows point out the attached adipose graft position in the treated patient. ECG shows a Q wave in leads III and aVF at baseline that is not present at follow-up ECGs.](gr4){#f0020}

###### 

Baseline clinical and MRI variables of the studied population.

Table 1

                                    AGTP-treated      Control                p-Value
  --------------------------------- ----------------- ---------------------- ---------
  Age                               63.8 ± 13         60.3 ± 6               0.6
  Risk factors                                                               
   Smoking current/past             2 (40)/3 (60)     3 (75)/1 (25)          0.3
   Hypertension                     4 (80)            2 (50)                 0.3
   Diabetes                         1 (20)            2 (50)                 0.3
  Dyslipidemia                      4 (80)            1 (25)                 0.1
  HR                                63 ± 7            61 ± 7                 0.6
  Q wave in ECG                     4 (80)            2 (50)                 0.3
  NYHA I/II/III                     0/4 (80)/1 (20)   1 (25)/2 (50)/1 (25)   0.6
  NTproBNP                          1066 ± 1084       1583 ± 1920            0.7
  Peak TnI                          3.1 ± 2.8         3.7 ± 2                0.7
  Surgical variables                                                         
   EuroSCORE                        5.4 ± 2.5         3.5 ± 1                0.2
   Logistic EuroSCORE, %            5.8 ± 4           2.9 ± 1                0.2
   Logistic EuroSCORE II, %         3.1 ± 2.3         1.8 ± 0.9              0.3
   Extracorporeal Circ. Time, min   76 ± 13           64 ± 23                0.4
   Ischemia time, min               37 ± 25           30 ± 20                0.7
   Grafts, n^o^.                    2.2 ± 0.8         2.0 ± 0.8              0.7
  MRI variables                                                              
   Necrosis mass, gr                34 ± 13           25 ± 4                 0.2
   Necrosis ratio, %                22 ± 9            18 ± 3                 0.4
   LVEF, %                          41 ± 18           42 ± 15                0.9
   LVESV, mL                        140 ± 83          128 ± 61               0.8
   LVEDV, mL                        220 ± 80          212 ± 46               0.8
   CO, L/min                        5.0 ± 0.8         5.1 ± 1.3              0.9

Data expressed in mean and standard deviation.

AGTP: Adipose Graft Transposition Procedure; HR: heart rate; NYHA: New York Heart Association; NTproBNP: N-terminal pro-B-type natriuretic peptide; ECG: electrocardiogram; TnI: Troponin I; LVEF: left ventricular ejection fraction; LVESV: left ventricular end systolic volume; LVEDV: left ventricular end diastolic volume; CO: cardiac output.

###### 

Patient interventional characteristics.

Table 2

  Patient   EuroSCORE   Logistic EuroSCORE[a](#tf0005){ref-type="table-fn"}   Logistic EuroSCORE II[a](#tf0005){ref-type="table-fn"}   ECC   ECC time   Ischemia time   N^o^ grafts   Study arm   AGTP location
  --------- ----------- ----------------------------------------------------- -------------------------------------------------------- ----- ---------- --------------- ------------- ----------- ---------------
  1         3           2.40%                                                 1.16%                                                    Yes   92         62              3             AGTP        Inferior
  3         8           10.19%                                                6.69%                                                    Yes   61         32              2             AGTP        Inferior
  4         4           3.51%                                                 2.39%                                                    No    --         0               1             Control     --
  5         3           2.07%                                                 0.95%                                                    Yes   81         57              3             AGTP        Inferior
  6         4           3.76%                                                 1.89%                                                    Yes   89         44              3             Control     --
  7         8           10.06%                                                3.56%                                                    No    --         0               1             AGTP        Inferior
  8         4           2.89%                                                 2.44%                                                    Yes   44         32              2             Control     --
  9         5           4.38%                                                 3.05%                                                    Yes   70         32              2             AGTP        Anterior
  10        2           1.51%                                                 0.58%                                                    Yes   60         42              2             Control     --

ECC: extracorporeal circulation; AGTP: Adipose Graft Transposition Procedure.

Percentage of predicted operative mortality for patients undergoing cardiac surgery by logistic EuroSCORE I and II formulas.

###### 

Safety results.

Table 3

                                                                      AGTP-treated   Control       p-Value
  ------------------------------------------------------------------- -------------- ------------- ---------
  Total adverse events                                                3              2             0.8
  Death                                                               1              0             0.6
  Hospital admission                                                  1              1             0.7
  New supraventricular arrhythmias[a](#tf0010){ref-type="table-fn"}   0              0             
  New ventricular arrhythmias[a](#tf0010){ref-type="table-fn"}        1              1             0.9
  Changes in number of SVEB[b](#tf0015){ref-type="table-fn"}          + 30 ± 28      + 209 ± 731   0.7
  Changes in number of VEB[b](#tf0015){ref-type="table-fn"}           − 331 ± 280    − 158 ± 218   0.3

AGTP: Adipose Graft Transposition Procedure; SVEB: supraventricular ectopi beats; VEB: ventricular ectopi beats.

Tachycardia defined as three or more beats, taking as reference the pre-intervention 24-h Holter monitoring. Ventricular arrhythmias were asymptomatic non-sustained monomorphic ventricular tachycardia.

Mean number from post-intervention Holter vs. pre-intervention Holter.

###### 

Mean MRI values at baseline, three months and one year follow-up.

Table 4

                      AGTP-treated   Control                           
  ------------------- -------------- --------- ------- ------- ------- -------
  Necrosis mass, gr   33.9           32.9      30.0    25.2    23.8    22.4
  Necrosis ratio, %   22.3           20.1      19.3    18.4    20.2    17.8
  LVEF, %             41             43        47      42      47      46
  LVESV, mL           139.6          131.9     114.9   127.8   99.2    104.6
  LVEDV, mL           219.8          218.0     202.4   212.2   187.7   194.6
  CO, L/min           5.0            5.5       5.8     5.1     5.9     5.5
  SV, mL              80.2           87.3      87.5    84.4    88.5    90.1

Data expressed in mean and standard deviation. No statistically significant differences were observed.

AGTP: Adipose Graft Transposition Procedure; LVEF: left ventricular ejection fraction; LVESV: left ventricular end systolic volume; LVEDV: left ventricular end diastolic volume; CO: cardiac output; SV: stroke volume.
